Literature DB >> 9422174

Pneumonia in ventilated head trauma patients: the role of thiopental therapy.

P Nadal1, J M Nicolás, C Font, A Vilella, S Nogué.   

Abstract

The role of barbiturate therapy in the development of pneumonia in head trauma patients in the intensive care unit of a university hospital was studied retrospectively. A total of 151 ventilated head trauma patients were included in the study. Intravenous thiopentone was administered to 75 patients (Group A), and 76 patients were managed without thiopentone therapy (Group B). Pneumonia was diagnosed when a new persistent pulmonary infiltrate appeared, with at least two of the following: (a) fever greater than 38 degrees C, (b) a white blood cell count greater than 15,000/mm3, or (c) the presence of purulent bronchial secretions. On admission, there were no differences in the acute physiology and chronic health evaluation 2 revision (APACHE II) and Glasgow Coma Score between Groups A and B. Fifty-three per cent of the patients treated with thiopentone (Group A) developed pneumonia compared with 35% in Group B (odds ratio 1.85, 95% confidence interval 0.97-3.51). Gram-negative and Staphylococcus aureus organisms were the most frequently isolated in all cases. No differences in age, sex, APACHE II, Glasgow Coma Score, nutritional status or dexamethasone treatment were observed between the groups with and without pulmonary infection. In the multivariate analysis, prolonged mechanical ventilation before pneumonia and thiopentone treatment remained as the only independent risk factors for the appearance of pneumonia in head trauma patients (p = 0.001 for both). Nevertheless, thiopentone did not increase the rate of mortality in patients with pneumonia. In conclusion, head trauma victims treated with thiopentone have a greater risk for the development of nosocomial pneumonia independent of mechanical ventilation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9422174     DOI: 10.1097/00063110-199503000-00004

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  6 in total

1.  Risk factors and pathogens involved in early ventilator-acquired pneumonia in patients with severe subarachnoid hemorrhage.

Authors:  R Cinotti; A Dordonnat-Moynard; F Feuillet; A Roquilly; N Rondeau; D Lepelletier; J Caillon; N Asseray; Y Blanloeil; B Rozec; K Asehnoune
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-10       Impact factor: 3.267

Review 2.  Intensive Care Unit-acquired infection as a side effect of sedation.

Authors:  Saad Nseir; Demosthenes Makris; Daniel Mathieu; Alain Durocher; Charles-Hugo Marquette
Journal:  Crit Care       Date:  2010-03-15       Impact factor: 9.097

3.  Traumatic brain injury: Intracranial pressure monitoring in traumatic brain injury.

Authors:  Bertil Romner; Per-Olof Grände
Journal:  Nat Rev Neurol       Date:  2013-03-12       Impact factor: 42.937

4.  Anaesthetic impairment of immune function is mediated via GABA(A) receptors.

Authors:  Daniel W Wheeler; Andrew J Thompson; Federico Corletto; Jill Reckless; Justin C T Loke; Nicolas Lapaque; Andrew J Grant; Pietro Mastroeni; David J Grainger; Claire L Padgett; John A O'Brien; Nigel G A Miller; John Trowsdale; Sarah C R Lummis; David K Menon; John S Beech
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

5.  Risk factors for early-onset ventilator-associated pneumonia in aneurysmal subarachnoid hemorrhage patients.

Authors:  J B Cui; Q Q Chen; T T Liu; S J Li
Journal:  Braz J Med Biol Res       Date:  2018-05-17       Impact factor: 2.590

6.  Early use of barbiturates is associated with increased mortality in traumatic brain injury patients from a propensity score-based analysis of a prospective cohort.

Authors:  Maxime Léger; Denis Frasca; Antoine Roquilly; Philippe Seguin; Raphaël Cinotti; Claire Dahyot-Fizelier; Karim Asehnoune; Florent Le Borgne; Thomas Gaillard; Yohann Foucher; Sigismond Lasocki
Journal:  PLoS One       Date:  2022-05-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.